Wenbin Jiang - Jan 9, 2023 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role: President and CEO, Director
Signature: /s/ Valerie Barnett, Attorney-in-Fact for Wenbin Jiang
Stock symbol: CTKB
Transactions as of: Jan 9, 2023
Transactions value $: -$213,200
Form type: 4
Date filed: 1/10/2023, 05:26 PM
Previous filing: Dec 9, 2022
Next filing: Feb 8, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CTKB	Common Stock	Sale	-$213K	-20K	-0.26%	$10.66	7.74M	Jan 9, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.47 to $10.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Content

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.47 to $10.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.